Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CalciMedica Inc CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).


NDAQ:CALC - Post by User

Post by alphaflighton Apr 15, 2021 11:38pm
551 Views
Post# 33008971

Graycliff Exploration Fully Funded Through to 2022 $2.4M PP

Graycliff Exploration Fully Funded Through to 2022 $2.4M PP

TORONTO, ON / ACCESSWIRE / April 15, 2021 / Graycliff Exploration Limited (the “Company” or “Graycliff“) (CSE:GRAY)(OTCQB:GRYCF)(FSE:GE0) is pleased to report the completion of a non-brokered private placement offering of 1,246,333 non-flow-through units (the “NFT Unit“) at $0.75 per NFT Unit and 1,875,000 flow-through shares (“FT Share“) at a price of $0.80 per FT Share of the Company (the “Financing“) for gross proceeds of $2,434,750.

Each NFT Unit consists of one common share which is not a “flow-through” share and one-half purchase warrant (“NFT Warrant“). Each whole NFT Warrant will entitle the holder to purchase one additional common share which is not a “flow-through” share at a price of $1.00 for two years from the closing.

“We are pleased to report that, with the completion of this private placement, we are now fully funded through to 2022 and will extend our exploration drilling at Shakespeare to phase 3. Presently, we are well into our phase 2 drilling with the completion of 11 holes and expect to start releasing assay results later this quarter,” Stated James Macintosh, President, and CEO. “We would like to welcome all of our new investors and extend our gratitude for the support from both existing and new shareholders. We look forward to continuing to de-risk Shakespeare.”

Graycliff intends to use the net proceeds from the Financing to continue the exploration program at the Company’s Shakespeare Project in Ontario, Canada.

The Company paid finder’s fee commissions of $167,808 cash and issued 214,993 finder’s warrants on the Financing. Each finder’s warrant has a strike price of $0.75 per share and an expiry two years from the closing.

The Company also provides comments regarding the recent trading activity. Graycliff’s Management is unaware of any material change in the Company that would account for the recent market volatility.

About Graycliff Exploration Limited

Graycliff Exploration is a mineral exploration company focused on its 945 hectares of prospective ground, located roughly 80 kilometres west of Sudbury on the prolific Canadian Shield. The Company’s Shakespeare Project consists of one crown patented lease, two crown leases and 40 claims on a property associated with the historic Shakespeare Gold Mine, which operated from 1903 to 1907.

For more information, contact investor relations at investors@graycliffexploration.com.

On Behalf of the Board of Directors,
James Macintosh
President and CEO


<< Previous
Bullboard Posts
Next >>